Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Zhong, L., Srinivas, S., Pon, V., Nicole Nguyen, N., Frear, M., Kwan, S., Gong, C., Malmstrom, R., Loucks, A., Wilson, L. AMER SOC CLINICAL ONCOLOGY. 2012
View details for Web of Science ID 000318009802737